<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03523728</url>
  </required_header>
  <id_info>
    <org_study_id>EFC15392</org_study_id>
    <secondary_id>2017‐004084‐12</secondary_id>
    <secondary_id>U1111-1202-0775</secondary_id>
    <nct_id>NCT03523728</nct_id>
  </id_info>
  <brief_title>A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients</brief_title>
  <acronym>STAGED-PKD</acronym>
  <official_title>Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To determine the effect of venglustat on the rate of total kidney volume (TKV) growth and
      estimated glomerular filtration rate (eGFR) decline in patients at risk of rapidly
      progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD).

      Secondary Objectives:

        -  To determine the effect of venglustat on the rate of renal function decline (Stage 1)
           and on the rate of TKV growth (Stage 2).

        -  To evaluate the pharmacokinetics (PK) of venglustat in Autosomal Dominant Polycystic
           Kidney Disease patients (Stages 1 and 2).

        -  Safety/tolerability objective:

        -  To characterize the safety profile of venglustat (Stages 1 and 2).

        -  To evaluate the effect of venglustat on mood using Beck Depression Inventory II (BDI-II)
           (Stages 1 and 2).

        -  To evaluate the effect of venglustat on the lens by ophthalmological examination (Stages
           1 and 2).

        -  To evaluate change in nocturia based on patient reported diary (Stages 1 and 2).

        -  To evaluate the effect of venglustat on kidney concentrating ability by assessing urine
           osmolality (in patients not on diuretic) (Stage 2 only).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration per participant is 26 months (maximal) per stage, including a screening period
      of 15 days, run-in period of 2 weeks, a 24-month treatment period, and a follow-up 30 days
      after final dose of investigational medicinal product (IMP).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2018</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change in of total kidney volume (TKV)</measure>
    <time_frame>From baseline to 18 months</time_frame>
    <description>Annualized rate of change in total kidney volume (TKV) based on magnetic resonance imaging (MRI) from baseline to 18 months (Stage 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of change in eGFR</measure>
    <time_frame>From baseline to 24 months</time_frame>
    <description>Annualized rate of change in estimated glomerular filtration rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation) from baseline to 24 months (Stage 2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change in eGFR</measure>
    <time_frame>From baseline to 18 months</time_frame>
    <description>Annualized rate of change in eGFR (CKD-EPI equation) from baseline to 18 months (Stage 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in TKV</measure>
    <time_frame>From baseline to 18 months</time_frame>
    <description>Annualized rate of change in TKV based on MRI from baseline to 18 months (Stage 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urine osmolality</measure>
    <time_frame>From baseline to 24 months</time_frame>
    <description>Change in urine osmolality from baseline to 24 months (in patients not on diuretic) (Stage 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in nocturia</measure>
    <time_frame>Stage 1: From baseline to 18 months; Stage 2: From baseline to 24 months</time_frame>
    <description>Change in nocturia from baseline to 18 months (Stage 1) and from baseline to 24 months (Stage 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Stage 1: From baseline to 18 months; Stage 2: From baseline to 24 months</time_frame>
    <description>Number of adverse events (Stages 1 and 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of plasma concentration of venglustat</measure>
    <time_frame>Stage 1: Day 1, Months 1, 6, and 18; Stage 2: Months 6 and 24</time_frame>
    <description>Assessment of single time-point plasma concentration (Stages 1 and 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lens clarity</measure>
    <time_frame>Stage 1: From baseline to 18 months; Stage 2: From baseline to 24 months</time_frame>
    <description>Change in the lens clarity from baseline by ophthalmological examination (Stages 1 and 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score of Beck Depression Inventory-II (BDI-II)</measure>
    <time_frame>Stage 1: From baseline to 18 months; Stage 2: From baseline to 24 months</time_frame>
    <description>Change in score of BDI-II (Stages 1 and 2)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">640</enrollment>
  <condition>Polycystic Kidney, Autosomal Dominant</condition>
  <arm_group>
    <arm_group_label>Venglustat dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive venglustat dose 1 once daily for 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venglustat dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive venglustat dose 2 once daily for 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be given once daily (Stage 1 and Stage 2) for 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venglustat GZ402671</intervention_name>
    <description>Pharmaceutical form: capsule Route of administration: oral</description>
    <arm_group_label>Venglustat dose 1</arm_group_label>
    <arm_group_label>Venglustat dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: capsule Route of administration: oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female adult with Autosomal Dominant Polycystic Kidney Disease (ADPKD) with
             age at the time the consent is signed:

               1. between 18 to 50 years (both inclusive) for patients from Stage 1

               2. between 18 to 50 years (both inclusive) for patients from Stage 2 with eGFR
                  between 45 and 89.9 mL/min/1.73 m2 during screening period*

               3. between 18 to 55 years (both inclusive) for patients from Stage 2 with eGFR
                  between 30 and 44.9 mL/min/1.73 m2 during screening period.*

          -  Diagnosis of AKPKD in patients with a family history will be based on unified Pei
             criteria. In the absence of a family history, the diagnosis will be based on the
             presence of renal cysts bilaterally, totaling at least 20, in the absence of findings
             suggestive of other cystic renal diseases.

          -  Mayo Imaging Classification of ADPKD Class 1C, 1D or 1E**

             **Total kidney volume (TKV) must be confirmed by a central reader prior to Visit 3.

          -  Estimated glomerular filtration rate between 45 to 89.9 mL/min/1.73 m2 during
             screening period* (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) for
             Stage 1.

          -  Estimated glomerular filtration rate between 30 to 89.9 mL/min/1.73 m2 during
             screening period* (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) for
             Stage 2.

             *Eligibility will be confirmed by eGFR value from one of the two first
             pre-randomization eGFR measurements.

          -  Stable treatment regimen of antihypertensive therapy for at least 30 days prior to the
             screening visit for hypertensive patient.

          -  Able to read, comprehend, and respond to the study questionnaires.

          -  Patient has given voluntary written informed consent before performance of any study
             related procedures not part of standard medical care.

          -  Patient does not have access to tolvaptan at the time of study start or tolvaptan is
             not indicated for treatment of patient according to treating physician (patient does
             not meet recommended criteria for treatment, refuses to initiate or does not tolerate
             treatment with tolvaptan).

          -  The patient, if female of childbearing potential, must have a negative blood pregnancy
             test (β-human chorionic gonadotropin [β-hCG]) at the screening visit and a negative
             urine pregnancy test at the baseline visit.

          -  Female patients of childbearing potential and male patients must agree to practice
             true abstinence in line with their preferred and usual lifestyle or to use
             double-contraceptive methods (including a highly effective method of contraception for
             female participants of childbearing potential) for the entire duration of the study
             and for at least 6 weeks for females and 90 days for males following their last dose
             of study drug.

        Exclusion criteria:

          -  Systolic blood pressure &gt;160 mm Hg at Run-in and Baseline visits.

          -  Administration within 3 months prior to the screening visit of tolvaptan or other
             Polycystic Kidney Disease-modifying agents (somatostatin analogues).

          -  Current participation in another investigational interventional study or use of
             investigational medicinal product (IMP), within 3 months or 5 half lives, whichever is
             longer, before randomization.

          -  The patient has a positive result of any of the following tests: hepatitis B surface
             antigen (HBsAg), anti-hepatitis C virus (anti HCV) antibodies, anti-human
             immunodeficiency virus 1 and 2 antibodies (anti HIV1 and anti HIV2 Ab). Patients with
             a positive hepatitis B surface antibody (HBsAb) test are eligible if other criteria
             are met (ie, negative tests for: HBsAg, hepatitis B core antibody [HBcAb]). Patients
             immune due to natural infection (positive hepatitis B surface antigen (HBsAb),
             negative hepatitis B surface antibody (HBsAg) and positive hepatitis B core antibody
             [HBcAb]) are eligible if they have negative HBV DNA test.

          -  A history of drug and/or alcohol abuse within the past year prior to the screening
             visit.

          -  The patient is scheduled for in-patient hospitalization including elective surgery,
             during the study.

          -  The patient has a clinically significant, uncontrolled medical condition that, in the
             opinion of the investigator, would put the safety of the subject at risk through
             participation, or which would affect the efficacy or safety analysis if the condition
             exacerbated during the study, or that may significantly interfere with study
             compliance, including all prescribed evaluations and follow-up activities.

          -  The patient, in the opinion of the investigator, is unable to adhere to the
             requirements of the study or unable to undergo study assessments (eg, has
             contraindications to pupillary dilation or unable to undergo magnetic resonance
             imaging (MRI) [For example: patient's weight exceeds weight capacity of the MRI,
             ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large
             abdominal/back tattoos, etc]).

          -  Any country-related specific regulation that would prevent the patient from entering
             the study.

          -  The patients did not adhere to treatment (&lt;70% compliance rate) in the run-in.

          -  The patient has, according to World Health Organization (WHO) Grading, a cortical
             cataract &gt;one-quarter of the lens circumference (Grade cortical cataract-2 [COR-2]) or
             a posterior subcapsular cataract &gt;2 mm (Grade posterior subcapsular cataract-2
             [PSC-2]). Patients with nuclear cataracts will not be excluded.

          -  The patient is currently receiving potentially cataractogenic medications, including a
             chronic regimen (more frequently than every 2 weeks) of any route of corticosteroids
             (including medium and high potency topical steroids) or any medication that may cause
             cataract, according to the Prescribing Information.

          -  The patient has received strong or moderate inducers or inhibitors of CYP3A4 within 14
             days or 5 half-lives, whichever is longer, prior to randomization. This also includes
             the consumption of grapefruit, grapefruit juice, or grapefruit containing products
             within 72 hours of starting venglustat administration.

          -  The patient is pregnant, or lactating.

          -  Liver enzymes (alanine aminotransferase [ALT]/aspartate aminotransferase [AST]) or
             total bilirubin &gt;2 times the upper limit of normal unless the patient has the
             diagnosis of Gilbert syndrome. Patients with the Gilbert syndrome should have no
             additional symptoms or signs which suggest hepatobiliary disease and serum total
             bilirubin level no more than 3mg/dl (51 μmol/L) with conjugated bilirubin less than
             20% of the total bilirubin fraction.

          -  Presence of severe depression as measured by Beck Depression Inventory-II (BDI-II) &gt;28
             and/or a history of a major affective disorder within 1 year of the screening visit.

          -  Known hypersensitivity to venglustat or any component of the excipients.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>https://pkdclinicaltrial.org or (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Please see More Information--&gt;Other Resources section below for additional links to see if you may qualify for the trial</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Investigational Site Number 8400002</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400017</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400001</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400008</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400010</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400004</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400007</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400014</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400003</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400021</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400016</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400020</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400011</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400015</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400019</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400005</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400006</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0360002</name>
      <address>
        <city>Herston</city>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0360001</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0400001</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0400004</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0560001</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0560002</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240002</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240003</name>
      <address>
        <city>Montreal</city>
        <zip>H2W 1R7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240001</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560005</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560004</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560009</name>
      <address>
        <city>Guangzhou</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560006</name>
      <address>
        <city>Hangzhou</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560002</name>
      <address>
        <city>Hefei</city>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560007</name>
      <address>
        <city>Nanjing</city>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560001</name>
      <address>
        <city>Shanghai</city>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560003</name>
      <address>
        <city>Shenyang</city>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030001</name>
      <address>
        <city>Praha 2</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030002</name>
      <address>
        <city>Praha 4</city>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2080001</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2080002</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500004</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500003</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500002</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500001</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760001</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760002</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760010</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760007</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40210</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760009</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760005</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760003</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760011</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760004</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800002</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800001</name>
      <address>
        <city>Montichiari</city>
        <zip>25018</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800003</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920002</name>
      <address>
        <city>Bunkyo-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920005</name>
      <address>
        <city>Kamakura-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920006</name>
      <address>
        <city>Kawasaki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920010</name>
      <address>
        <city>Kyoto-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920009</name>
      <address>
        <city>Nagoya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920003</name>
      <address>
        <city>Niigata-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920007</name>
      <address>
        <city>Osaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920001</name>
      <address>
        <city>Sapporo-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920004</name>
      <address>
        <city>Shinjuku-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920008</name>
      <address>
        <city>Toyoake-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100001</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100002</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5280001</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5280002</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6200004</name>
      <address>
        <city>Almada</city>
        <zip>2801-951</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6200001</name>
      <address>
        <city>Loures</city>
        <zip>2674-514</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6420002</name>
      <address>
        <city>Bucuresti</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6420001</name>
      <address>
        <city>Timisoara</city>
        <zip>300723</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240003</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240001</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240002</name>
      <address>
        <city>Madrid / Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1580001</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1580002</name>
      <address>
        <city>Taipei</city>
        <zip>10043</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8260001</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pkdclinicaltrial.org/?utm_source=ctgov</url>
    <description>For more information in the USA, please click here</description>
  </link>
  <link>
    <url>https://adpkdclinicaltrial.jp/?utm_source=ctgov</url>
    <description>For more information in Japan, please click here</description>
  </link>
  <link>
    <url>https://klinischestudieadpkd.eu/?utm_source=ctgov</url>
    <description>For more information in Germany/Austria, please click here</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 1, 2018</study_first_submitted>
  <study_first_submitted_qc>May 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2018</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

